HSPA5 and cancer: Intratumor injection of miR-122-exo noticeably improved the antitumor performance of sorafenib in HCC in vivo.41 Li et al.68 showed that the combination of si-GRP78-modified exosomes and sorafenib could target GRP78 in HCC cells and restrain cancer cells from growing and invading.